Capital Crunch Starting To Ease For Cancer Immunotherapy Space
Executive Summary
A year later, biotech companies with cancer immunotherapies are beginning to reap the capital rewards of FDA's April 2010 approval of Dendreon's Provenge (sipuleucel-T) for prostate cancer.
You may also be interested in...
Potential Universal Cancer Vaccine Will Start Clinical Trials In Ovarian Cancer
Immunovaccine obtains approval from FDA to conduct a small Phase I trial followed immediately by a larger Phase II for DPX-Survivac in ovarian cancer.
Potential Universal Cancer Vaccine Will Start Clinical Trials In Ovarian Cancer
Immunovaccine obtains approval from FDA to conduct a small Phase I trial followed immediately by a larger Phase II for DPX-Survivac in ovarian cancer.
Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.